Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 6/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5234024 | 0.88 | ALDH1A1 (0.35) | AVPR1BCNR2GSK3BMAPK8SMN1; SMN2 | |
| SCHEMBL5234701 | 0.87 | MAPK8 (0.44) | AVPR1BCNR2GSK3BMAPK8SMN1; SMN2 | |
| SCHEMBL5238621 | 0.86 | PGR (0.39) | AVPR1BCNR2MAPK8SMN1; SMN2HRH2 | |
| SCHEMBL5234735 | 0.86 | DPP4 (0.37) | SMN1; SMN2ALDH1A1KDM4EHSD17B10TDP1 | |
| SCHEMBL5239411 | 0.85 | PTGER4 (0.32) | ALDH1A1KDM4EHSD17B10NPSR1PTGER4 | |
| SCHEMBL5234611 | 0.84 | DPP4 (0.42) | AVPR1BSMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL5234366 | 0.84 | ALDH1A1 (0.33) | AVPR1BCNR2SMN1; SMN2HIF1AHRH2 | |
| SCHEMBL5234286 | 0.83 | KMT2A (0.40) | AVPR1BCNR2SMN1; SMN2HRH1ALDH1A1 | |
| SCHEMBL6109025 | 0.82 | GSK3B (0.32) | AVPR1BGSK3BMAPK8HIF1A | |
| SCHEMBL5234032 | 0.81 | AVPR1B (0.35) | AVPR1BCNR2GSK3BMAPK8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | AVPR1B 1020/4885CNR2 3755/4885GSK3B 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.